Format

Send to

Choose Destination
Clin Appl Thromb Hemost. 2014 Sep;20(6):621-8. doi: 10.1177/1076029613480556. Epub 2013 Mar 11.

Anticoagulant and Antithrombotic Actions of AVE5026, an Enriched Anti-Xa Hemisynthetic Ultra-Low-Molecular-Weight Heparin.

Author information

1
Loyola University Chicago, Maywood, IL, USA dhoppen@lumc.edu.
2
Loyola University Chicago, Maywood, IL, USA.

Abstract

INTRODUCTION:

AVE5026 represents a new generation of ultra-low-molecular-weight heparin (LMWH) with high anti-Xa and low anti-IIa activities (anti Xa-IIa ratio >30). In addition, AVE5026 exhibits a relatively higher proportion of AT components.

MATERIALS AND METHODS:

The anticoagulant, antiplatelet, antithrombotic, and bleeding effects of AVE5026 in comparison to other heparins were investigated in this study.

RESULTS:

AVE5026 demonstrated weak effects in the global clotting assays; however, in the amidolytic anti-Xa assay, AVE5026 produced strong inhibitory effects. AVE5026 showed no cross-reactivity with the heparin-induced thrombocytopenia antibodies in the platelet aggregation system. AVE5026 produced a dose-dependent antithrombotic response after intravenous (IV) and subcutaneous (SC) administration in thrombosis models. The relative bleeding effects of AVE5026 in a rat tail bleeding and rabbit blood loss model were negligible after both IV and SC administration.

CONCLUSIONS:

This superior safety efficacy index in animal models in comparison with other LMWH may translate into improved antithrombotic efficacy with decreased bleeding risk.

KEYWORDS:

antithrombotic; bleeding; enriched anti-Xa activity; safety; ultra-low-molecular-weight heparin

PMID:
23482722
DOI:
10.1177/1076029613480556
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center